Diplomat Pharmacy (DPLO) Tops Q1 EPS by 4c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Diplomat Pharmacy (DPLO) PT Raised to $20 at Barclays; '1Q17 Beat & Maintain, Acquisition Expands Manufacturer Services'
May 9, 2017 12:50 PM EDTBarclays raised its price target on Diplomat Pharmacy (NYSE: DPLO) to $20.00 (from $17.00) while maintaining a Overweight rating, following the company's first quarter earnings report.
Analyst Eric Percher notes the company reported first quarter earnings per share above consensus and offered in-line revenue... More
Diplomat Pharmacy (DPLO) PT Raised to $17 at Cowen; Reiterates Market Perform
May 9, 2017 8:11 AM EDTCowen raised its price target on Diplomat Pharmacy (NYSE: DPLO) to $17.00 (from $12.00) while maintaining a Market Perform rating. DPLO reported 1Q revenues of $1.08B, which was in-line with consensus, due to acquisitions, manufacturing price increases and contributions from new drugs. Adjusted EPS of $0.19 also exceeded... More
